NO304311B1 - Tiazolidinon- og oksazolidinonderivater og farmas°ytisk preparat - Google Patents
Tiazolidinon- og oksazolidinonderivater og farmas°ytisk preparat Download PDFInfo
- Publication number
- NO304311B1 NO304311B1 NO921159A NO921159A NO304311B1 NO 304311 B1 NO304311 B1 NO 304311B1 NO 921159 A NO921159 A NO 921159A NO 921159 A NO921159 A NO 921159A NO 304311 B1 NO304311 B1 NO 304311B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- denotes
- compound according
- carbon atoms
- hydrogen atom
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title description 5
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 38
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 13
- 125000003118 aryl group Chemical group 0.000 claims abstract description 11
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 43
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 206010065929 Cardiovascular insufficiency Diseases 0.000 claims description 5
- 239000003218 coronary vasodilator agent Substances 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- IVAGZWHXWLCLSB-UHFFFAOYSA-N 2-[(5-benzyl-2-oxo-1,3-thiazolidine-4-carbonyl)amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)C1NC(=O)SC1CC1=CC=CC=C1 IVAGZWHXWLCLSB-UHFFFAOYSA-N 0.000 claims description 3
- HBNQBNBZAPOSBW-UHFFFAOYSA-N 2-[[5-(4-methoxyphenyl)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]ethyl nitrate Chemical compound C1=CC(OC)=CC=C1C1C(C(=O)NCCO[N+]([O-])=O)NC(=O)S1 HBNQBNBZAPOSBW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 3
- WSPFZJVPRYXFFX-UHFFFAOYSA-N 2-[(2-oxo-1,3-thiazolidine-4-carbonyl)amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)C1CSC(=O)N1 WSPFZJVPRYXFFX-UHFFFAOYSA-N 0.000 claims description 2
- SZNHDFQTDIMGRV-UHFFFAOYSA-N 2-[(2-oxo-1,3-thiazolidine-5-carbonyl)amino]ethyl nitrate Chemical group [O-][N+](=O)OCCNC(=O)C1CNC(=O)S1 SZNHDFQTDIMGRV-UHFFFAOYSA-N 0.000 claims description 2
- YFGQVZFEOCXAEE-UHFFFAOYSA-N 2-[[4-(4-methoxyphenyl)-2-oxo-1,3-thiazolidine-5-carbonyl]amino]ethyl nitrate Chemical group C1=CC(OC)=CC=C1C1C(C(=O)NCCO[N+]([O-])=O)SC(=O)N1 YFGQVZFEOCXAEE-UHFFFAOYSA-N 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000000304 vasodilatating effect Effects 0.000 abstract description 11
- 150000002148 esters Chemical class 0.000 abstract description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000005864 Sulphur Substances 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- 238000006243 chemical reaction Methods 0.000 description 61
- 238000000034 method Methods 0.000 description 45
- 239000002904 solvent Substances 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 36
- -1 1- methylpentyl Chemical group 0.000 description 31
- 239000013078 crystal Substances 0.000 description 31
- 238000004821 distillation Methods 0.000 description 28
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26
- HEIWCRRLFLDZIT-UHFFFAOYSA-N 2-aminoethyl nitrate;nitric acid Chemical compound O[N+]([O-])=O.NCCO[N+]([O-])=O HEIWCRRLFLDZIT-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000002253 acid Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000001816 cooling Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 150000004820 halides Chemical class 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000000376 reactant Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000012442 inert solvent Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 150000008065 acid anhydrides Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 150000008282 halocarbons Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000010579 first pass effect Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- UCDHYFZYUGDETN-UHFFFAOYSA-N cyanophosphonic acid Chemical compound OP(O)(=O)C#N UCDHYFZYUGDETN-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002140 halogenating effect Effects 0.000 description 3
- 231100000989 no adverse effect Toxicity 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- SQZYWKSLUDQBEN-LURJTMIESA-N (4r)-n-(4-hydroxybutyl)-2-oxo-1,3-thiazolidine-4-carboxamide Chemical compound OCCCCNC(=O)[C@@H]1CSC(=O)N1 SQZYWKSLUDQBEN-LURJTMIESA-N 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- RTVINSXFBCULIV-UHFFFAOYSA-N 2-[(2-oxo-5-thiophen-2-yl-1,3-thiazolidine-4-carbonyl)amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)C1NC(=O)SC1C1=CC=CS1 RTVINSXFBCULIV-UHFFFAOYSA-N 0.000 description 2
- WSPFZJVPRYXFFX-SCSAIBSYSA-N 2-[[(4s)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)[C@H]1CSC(=O)N1 WSPFZJVPRYXFFX-SCSAIBSYSA-N 0.000 description 2
- BMLMGCPTLHPWPY-UHFFFAOYSA-N 2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSC(=O)N1 BMLMGCPTLHPWPY-UHFFFAOYSA-N 0.000 description 2
- XAUYBXHQDHHHGE-UHFFFAOYSA-N 2-oxo-1,3-thiazolidine-5-carboxylic acid Chemical compound OC(=O)C1CNC(=O)S1 XAUYBXHQDHHHGE-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- KBKJNLSBGBBDHX-UHFFFAOYSA-N 3-amino-2-(2-phenylethanethioyl)sulfanylpropanoic acid;hydrochloride Chemical compound Cl.NCC(C(O)=O)SC(=S)CC1=CC=CC=C1 KBKJNLSBGBBDHX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000006307 alkoxy benzyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000005179 haloacetyl group Chemical group 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000000802 nitrating effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- UTANVRJWTDLNNZ-UHFFFAOYSA-N nitric acid thionyl dichloride Chemical compound O[N+]([O-])=O.ClS(Cl)=O UTANVRJWTDLNNZ-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- ZWHOTPNCEFWATE-AWEZNQCLSA-N (3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-AWEZNQCLSA-N 0.000 description 1
- IZSRRYSOHJAGLW-BYPYZUCNSA-N (4r)-n-(2-hydroxyethyl)-2-oxo-1,3-thiazolidine-4-carboxamide Chemical compound OCCNC(=O)[C@@H]1CSC(=O)N1 IZSRRYSOHJAGLW-BYPYZUCNSA-N 0.000 description 1
- JPBQRAMZSMZGGU-GBXIJSLDSA-N (4r,5r)-5-methyl-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound C[C@H]1SC(=O)N[C@@H]1C(O)=O JPBQRAMZSMZGGU-GBXIJSLDSA-N 0.000 description 1
- HLEWENVVLNOPPW-GBXIJSLDSA-N (4r,5s)-4-methyl-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound C[C@H]1NC(=O)O[C@@H]1C(O)=O HLEWENVVLNOPPW-GBXIJSLDSA-N 0.000 description 1
- XMFFFMBLTDERID-REOHCLBHSA-N (4s)-2-oxo-1,3-oxazolidine-4-carboxylic acid Chemical compound OC(=O)[C@@H]1COC(=O)N1 XMFFFMBLTDERID-REOHCLBHSA-N 0.000 description 1
- BMLMGCPTLHPWPY-UWTATZPHSA-N (4s)-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=O)N1 BMLMGCPTLHPWPY-UWTATZPHSA-N 0.000 description 1
- SYJOFPCRKHOCEG-JGVFFNPUSA-N (4s,5r)-2-oxo-5-phenyl-1,3-oxazolidine-4-carboxylic acid Chemical compound OC(=O)[C@H]1NC(=O)O[C@@H]1C1=CC=CC=C1 SYJOFPCRKHOCEG-JGVFFNPUSA-N 0.000 description 1
- HLEWENVVLNOPPW-STHAYSLISA-N (4s,5r)-4-methyl-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound C[C@@H]1NC(=O)O[C@H]1C(O)=O HLEWENVVLNOPPW-STHAYSLISA-N 0.000 description 1
- KYNKAUUXUQOZSQ-GBXIJSLDSA-N (4s,5r)-5-methyl-2-oxo-1,3-oxazolidine-4-carboxylic acid Chemical compound C[C@H]1OC(=O)N[C@@H]1C(O)=O KYNKAUUXUQOZSQ-GBXIJSLDSA-N 0.000 description 1
- ITQZGBLSWNNLFL-UWTATZPHSA-N (5r)-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)[C@H]1CNC(=O)O1 ITQZGBLSWNNLFL-UWTATZPHSA-N 0.000 description 1
- ITQZGBLSWNNLFL-REOHCLBHSA-N (5s)-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)[C@@H]1CNC(=O)O1 ITQZGBLSWNNLFL-REOHCLBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- GTUHILNORYSYGY-UHFFFAOYSA-N 1-[azido-(4-nitrophenyl)phosphoryl]-4-nitrobenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1P(=O)(N=[N+]=[N-])C1=CC=C([N+]([O-])=O)C=C1 GTUHILNORYSYGY-UHFFFAOYSA-N 0.000 description 1
- UVNRLVNSVHJHQE-UHFFFAOYSA-N 1-aminopropan-2-yl nitrate;nitric acid Chemical compound O[N+]([O-])=O.NCC(C)O[N+]([O-])=O UVNRLVNSVHJHQE-UHFFFAOYSA-N 0.000 description 1
- YRUDGXVALAXJFA-UHFFFAOYSA-N 2-(methylamino)ethyl nitrate;nitric acid Chemical compound O[N+]([O-])=O.CNCCO[N+]([O-])=O YRUDGXVALAXJFA-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QADHLWAQVDWCGD-UHFFFAOYSA-N 2-[(2-oxo-5-pyridin-3-yl-1,3-thiazolidine-4-carbonyl)amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)C1NC(=O)SC1C1=CC=CN=C1 QADHLWAQVDWCGD-UHFFFAOYSA-N 0.000 description 1
- AEEQYWABIYSFMY-UHFFFAOYSA-N 2-[(3-methyl-2-oxo-1,3-thiazolidine-4-carbonyl)amino]ethyl nitrate Chemical compound CN1C(C(=O)NCCO[N+]([O-])=O)CSC1=O AEEQYWABIYSFMY-UHFFFAOYSA-N 0.000 description 1
- WSPFZJVPRYXFFX-BYPYZUCNSA-N 2-[[(4r)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)[C@@H]1CSC(=O)N1 WSPFZJVPRYXFFX-BYPYZUCNSA-N 0.000 description 1
- IKJVLZIBMKJVGH-UHNVWZDZSA-N 2-[[(4r,5r)-5-methyl-2-oxo-1,3-thiazolidine-4-carbonyl]amino]ethyl nitrate Chemical compound C[C@H]1SC(=O)N[C@@H]1C(=O)NCCO[N+]([O-])=O IKJVLZIBMKJVGH-UHNVWZDZSA-N 0.000 description 1
- VIERMOJDBYEKAM-UHFFFAOYSA-N 2-[[5-(3-nitrophenyl)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)C1NC(=O)SC1C1=CC=CC([N+]([O-])=O)=C1 VIERMOJDBYEKAM-UHFFFAOYSA-N 0.000 description 1
- IWOKAHZQVQEFAU-UHFFFAOYSA-N 2-[[5-(4-chlorophenyl)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)C1NC(=O)SC1C1=CC=C(Cl)C=C1 IWOKAHZQVQEFAU-UHFFFAOYSA-N 0.000 description 1
- QJDJEYPXRYEBEQ-UHFFFAOYSA-N 2-[[5-(furan-2-yl)-2-oxo-1,3-thiazolidine-4-carbonyl]amino]ethyl nitrate Chemical compound [O-][N+](=O)OCCNC(=O)C1NC(=O)SC1C1=CC=CO1 QJDJEYPXRYEBEQ-UHFFFAOYSA-N 0.000 description 1
- JUVFZCVBZKOUEL-UHFFFAOYSA-N 2-aminopropyl nitrate;nitric acid Chemical compound O[N+]([O-])=O.CC(N)CO[N+]([O-])=O JUVFZCVBZKOUEL-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- WEIGDWIZZXHFRS-UHFFFAOYSA-N 2-oxo-4-phenyl-1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)C1OC(=O)NC1C1=CC=CC=C1 WEIGDWIZZXHFRS-UHFFFAOYSA-N 0.000 description 1
- POMKAGNYRCNCDN-UHFFFAOYSA-N 2-oxo-5-phenyl-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1C1=CC=CC=C1 POMKAGNYRCNCDN-UHFFFAOYSA-N 0.000 description 1
- LESJYNUOKFROMZ-UHFFFAOYSA-N 2-oxo-5-pyridin-3-yl-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1C1=CC=CN=C1 LESJYNUOKFROMZ-UHFFFAOYSA-N 0.000 description 1
- MFEHMOTYLUMKLA-UHFFFAOYSA-N 2-oxo-5-thiophen-2-yl-1,3-oxazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)OC1C1=CC=CS1 MFEHMOTYLUMKLA-UHFFFAOYSA-N 0.000 description 1
- WORCSJRFGOHTFL-UHFFFAOYSA-N 2-oxo-5-thiophen-2-yl-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1C1=CC=CS1 WORCSJRFGOHTFL-UHFFFAOYSA-N 0.000 description 1
- ZKIATGYXDBASFQ-UHFFFAOYSA-N 3-[(2-oxo-1,3-thiazolidine-4-carbonyl)amino]propyl nitrate Chemical compound [O-][N+](=O)OCCCNC(=O)C1CSC(=O)N1 ZKIATGYXDBASFQ-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 1
- ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- VVPGEFWZAXBZHR-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]sulfanyl-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)SC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 VVPGEFWZAXBZHR-UHFFFAOYSA-N 0.000 description 1
- PRXYGWCVUQFOOD-UHFFFAOYSA-N 3-aminopropyl nitrate;nitric acid Chemical compound O[N+]([O-])=O.NCCCO[N+]([O-])=O PRXYGWCVUQFOOD-UHFFFAOYSA-N 0.000 description 1
- PXRGHOQPKGNIKU-UHFFFAOYSA-N 3-methyl-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound CN1C(C(O)=O)CSC1=O PXRGHOQPKGNIKU-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- QEIVWSRXBYOTAZ-UHFFFAOYSA-N 4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1CCN(CC1)C(=O)NC1=CC=CC=C1 QEIVWSRXBYOTAZ-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- FDLWNABUNDRNIM-UHFFFAOYSA-N 5,5-dimethyl-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound CC1(C)SC(=O)NC1C(O)=O FDLWNABUNDRNIM-UHFFFAOYSA-N 0.000 description 1
- MKXQQUMKUXMISJ-UHFFFAOYSA-N 5-(3-nitrophenyl)-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1C1=CC=CC([N+]([O-])=O)=C1 MKXQQUMKUXMISJ-UHFFFAOYSA-N 0.000 description 1
- ASHPTOLOBOZDEN-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1C1=CC=C(Cl)C=C1 ASHPTOLOBOZDEN-UHFFFAOYSA-N 0.000 description 1
- HFMFOMRYNNYIRK-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1C(C(O)=O)NC(=O)S1 HFMFOMRYNNYIRK-UHFFFAOYSA-N 0.000 description 1
- RVWDOVKETIOTAR-UHFFFAOYSA-N 5-(furan-2-yl)-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1C1=CC=CO1 RVWDOVKETIOTAR-UHFFFAOYSA-N 0.000 description 1
- MLONTGNHFQBZQT-UHFFFAOYSA-N 5-benzyl-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1CC1=CC=CC=C1 MLONTGNHFQBZQT-UHFFFAOYSA-N 0.000 description 1
- DZCBAAZMZPYDTA-UHFFFAOYSA-N 5-naphthalen-1-yl-2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1NC(=O)SC1C1=CC=CC2=CC=CC=C12 DZCBAAZMZPYDTA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000052583 Anaphase-Promoting Complex-Cyclosome Apc8 Subunit Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000912124 Homo sapiens Cell division cycle protein 23 homolog Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LPMHDYUMNBBOKR-UHFFFAOYSA-N dimethoxyphosphorylformonitrile Chemical compound COP(=O)(OC)C#N LPMHDYUMNBBOKR-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/14—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6308891 | 1991-03-27 | ||
| JP10275191 | 1991-05-08 | ||
| JP33030491 | 1991-12-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO921159D0 NO921159D0 (no) | 1992-03-25 |
| NO921159L NO921159L (no) | 1992-09-28 |
| NO304311B1 true NO304311B1 (no) | 1998-11-30 |
Family
ID=27298042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO921159A NO304311B1 (no) | 1991-03-27 | 1992-03-25 | Tiazolidinon- og oksazolidinonderivater og farmas°ytisk preparat |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US5298516A (da) |
| EP (1) | EP0506434B1 (da) |
| JP (1) | JPH0780859B2 (da) |
| KR (1) | KR0152097B1 (da) |
| CN (2) | CN1031824C (da) |
| AT (1) | ATE118770T1 (da) |
| AU (1) | AU647599B2 (da) |
| CA (1) | CA2064108C (da) |
| CZ (1) | CZ282529B6 (da) |
| DE (1) | DE69201451T2 (da) |
| DK (1) | DK0506434T3 (da) |
| ES (1) | ES2072095T3 (da) |
| FI (1) | FI106260B (da) |
| HK (1) | HK123595A (da) |
| HU (2) | HU217969B (da) |
| IE (1) | IE67383B1 (da) |
| IL (1) | IL101395A (da) |
| IS (1) | IS1746B (da) |
| NO (1) | NO304311B1 (da) |
| NZ (1) | NZ242154A (da) |
| PH (1) | PH30493A (da) |
| RU (1) | RU2055073C1 (da) |
| TW (1) | TW226015B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3454531B2 (ja) * | 1991-11-07 | 2003-10-06 | 三共株式会社 | ニトロキシアルキルアミド誘導体 |
| AU6376894A (en) * | 1993-03-15 | 1994-10-11 | Byk Nederland Bv | Use of substituted alkyl nitrates for the treatment of pathologically increased intra-ocular pressure |
| DE4429461A1 (de) * | 1994-08-19 | 1996-02-22 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE69522118T2 (de) * | 1994-12-15 | 2002-04-25 | Sankyo Co., Ltd. | Thiazolidonon- oder oxazolidinonderivate zur behandlung von angina pectoris und zusammensetzungen die diese als wirkstoffe enthält |
| DE69612967T2 (de) * | 1995-03-02 | 2002-04-04 | Sankyo Co., Ltd. | Optisch aktive thiazolidinonderivate |
| US5925658A (en) * | 1995-03-02 | 1999-07-20 | Sankyo Company, Limited | Optically active thiazolidinone derivative |
| AU6016496A (en) * | 1995-06-14 | 1997-01-15 | Sankyo Company Limited | Antianginal drug comprising nitroxy derivative as active ingredient |
| BE1010768A3 (nl) * | 1996-11-26 | 1999-01-05 | Dsm Nv | Een werkwijze voor de bereiding van alpha-aminozuuramiden, alpha-aminozuren en derivaten ervan. |
| IL120531A (en) * | 1997-03-26 | 2006-12-31 | Yissum Res Dev Co | Nitric oxide donors and pharmaceutical compositions containing them |
| WO2002069967A1 (fr) * | 2001-03-01 | 2002-09-12 | Sankyo Company, Limited | Compositions a absorption percutanee |
| WO2013016727A1 (en) * | 2011-07-28 | 2013-01-31 | Promentis Pharmaceuticals, Inc. | Cysteine prodrugs |
| US10239847B1 (en) | 2016-03-03 | 2019-03-26 | Cellactin | Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200640A (en) * | 1976-04-02 | 1980-04-29 | Chugai Seiyaku Kabushiki Kaisha | Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use |
| GB8717068D0 (en) * | 1987-07-20 | 1987-08-26 | Fujisawa Pharmaceutical Co | Nitric ester derivative |
| WO1990012791A1 (en) * | 1989-04-21 | 1990-11-01 | E.I. Du Pont De Nemours And Company | Fungicidal oxazolidinones |
-
1992
- 1992-03-24 AU AU13122/92A patent/AU647599B2/en not_active Ceased
- 1992-03-24 US US07/856,491 patent/US5298516A/en not_active Expired - Fee Related
- 1992-03-25 NO NO921159A patent/NO304311B1/no not_active IP Right Cessation
- 1992-03-26 IE IE920966A patent/IE67383B1/en not_active IP Right Cessation
- 1992-03-26 CA CA002064108A patent/CA2064108C/en not_active Expired - Fee Related
- 1992-03-26 TW TW081102328A patent/TW226015B/zh active
- 1992-03-26 FI FI921340A patent/FI106260B/fi not_active IP Right Cessation
- 1992-03-26 IS IS3828A patent/IS1746B/is unknown
- 1992-03-26 JP JP4067972A patent/JPH0780859B2/ja not_active Expired - Fee Related
- 1992-03-26 RU SU925011508A patent/RU2055073C1/ru not_active IP Right Cessation
- 1992-03-26 CZ CS92916A patent/CZ282529B6/cs not_active IP Right Cessation
- 1992-03-27 CN CN92103119A patent/CN1031824C/zh not_active Expired - Fee Related
- 1992-03-27 KR KR1019920005089A patent/KR0152097B1/ko not_active IP Right Cessation
- 1992-03-27 PH PH44131A patent/PH30493A/en unknown
- 1992-03-27 DE DE69201451T patent/DE69201451T2/de not_active Expired - Fee Related
- 1992-03-27 EP EP92302674A patent/EP0506434B1/en not_active Expired - Lifetime
- 1992-03-27 ES ES92302674T patent/ES2072095T3/es not_active Expired - Lifetime
- 1992-03-27 DK DK92302674.4T patent/DK0506434T3/da active
- 1992-03-27 AT AT92302674T patent/ATE118770T1/de not_active IP Right Cessation
- 1992-03-27 HU HU9201033A patent/HU217969B/hu not_active IP Right Cessation
- 1992-03-27 NZ NZ242154A patent/NZ242154A/xx unknown
- 1992-03-27 IL IL10139592A patent/IL101395A/en not_active IP Right Cessation
-
1993
- 1993-12-06 US US08/162,675 patent/US5356918A/en not_active Expired - Fee Related
-
1995
- 1995-05-26 CN CN95106819A patent/CN1096265C/zh not_active Expired - Fee Related
- 1995-06-29 HU HU95P/P00546P patent/HU211969A9/hu unknown
- 1995-07-27 HK HK123595A patent/HK123595A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69526862T2 (de) | Azol-derivate | |
| WO2002006237A1 (fr) | Medicament comprenant un derive de dicyanopyridine | |
| EP1200415A1 (en) | Diamino-1,2,4-triazole-carboxylic acid derivatives as gsk-3 inhibitors | |
| NO304311B1 (no) | Tiazolidinon- og oksazolidinonderivater og farmas°ytisk preparat | |
| CA2901696A1 (en) | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer | |
| KR860002036B1 (ko) | 히스타민 h₂-길항제의 제조방법 | |
| DE69217252T2 (de) | Aminosäurederivat | |
| CA3088471A1 (en) | Novel compounds | |
| KR100230633B1 (ko) | 니트록시알킬아미드 유도체(Nitroxyalkylamide derivate) | |
| KR100293334B1 (ko) | 알킬렌디아민유도체 | |
| JPH0140027B2 (da) | ||
| CS254349B2 (en) | Method of new substituted isoxazole derivatives production | |
| US5240918A (en) | 2-(substituted imino)-thiazolidines and process for the preparation thereof | |
| EP0903346A1 (en) | Sydnone imine derivatives | |
| KR20230051940A (ko) | 신규한 캡시드 조립 저해제 | |
| WO2019126842A1 (en) | Therapeutic compounds and uses thereof | |
| KR20000016164A (ko) | 치환된 아미디노벤젠 유도체 및 이의 약제학적 조성물 | |
| JPH09227537A (ja) | シドノンイミン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |